Bayer Stages a Technical Recovery as CEO Threatens US Glyphosate Halt
05.06.2026 - 17:37:33 | boerse-global.de
The German chemical and pharmaceutical giant is navigating a precarious moment: its stock has clawed back above a key moving average, while the chief executive simultaneously escalates a confrontation that could pull a vital product from the American market.
On Friday, shares of Bayer ticked up to €36.24, a 2.5 per cent gain, lifting the stock back above its 200-day moving average of €35.80. The move came just days after a brutal 6 per cent-plus plunge on 2 June that sent the equity to a six-month low, triggered by a procedural shift in the sprawling US glyphosate class-action litigation. The current cushion above the long-term trendline is wafer-thin — barely 1.2 per cent — and hardly a stamp of stability, but it does raise the possibility that the earlier breakdown was a false signal.
The technical picture remains cluttered with resistance. The 50-day average sits at €38.40 and the 100-day at €40.50, forming a dense band between €38 and €41 that must be breached before any durable uptrend can be declared. The relative strength index, at 44.3, is neutral territory; momentum traders have little reason to pile in. Adding to the unease, annualised 30-day volatility has hit nearly 37 per cent — abnormally high for a DAX heavyweight and a reflection of how deeply court headlines now dominate the company’s price action.
Behind the charting drama, CEO Bill Anderson has turned up the heat. With more than 100,000 lawsuits over the weedkiller still pending, plaintiff attorneys are attempting to move cases from Missouri to a California federal judge regarded as notably hostile to Bayer. Anderson is fighting that move in court while simultaneously raising the stakes on the political front. He has threatened to halt all glyphosate production in the United States unless a permanent legal solution is found — an ultimatum that, if carried out, would rattle American agriculture. The threat is not empty rhetoric; it underscores how deeply the company’s past is consuming its present.
Should investors sell immediately? Or is it worth buying Bayer?
Away from the courtroom, Bayer’s underlying business is performing respectably. First-quarter 2026 earnings per share comfortably beat expectations. The Crop Science division benefited from lucrative licensing deals, and the Consumer Health unit also showed growth. The company carries a market capitalisation of roughly €33.5 billion. The real drain is cash. Free cash flow for the full year is being savaged by settlement payouts, diverting money that could otherwise fund research and expansion. Major shareholders are losing patience. Union Investment recently articulated the frustration bluntly: Bayer needs margins, not visions — profits, not promises.
Management has so far ruled out spinning off the Monsanto agriculture business, insisting it can resolve the legal entanglement within the existing structure, though it keeps the rhetorical door open to “all options”. That balancing act captures the strategic bind.
The next big catalyst looms in Washington. The US Supreme Court is expected to rule on a key case — Durnell — by the end of July 2026, though some reports have flagged a broader glyphosate-related decision as early as the end of June. A favourable verdict for Bayer would sharply curtail its liability exposure and potentially pave the way for a comprehensive legal settlement. An adverse outcome, however, would turn Anderson’s production-stop threat into a very real contingency.
Bayer at a turning point? This analysis reveals what investors need to know now.
Year to date, Bayer shares remain down roughly 5 per cent, nearly all the gains from February having been surrendered. On a 12-month basis, they are still up about 38 per cent — a reminder of how far the stock has swung on legal news. With the 200-day line reclaimed but the resistance zone ahead, and with a Supreme Court decision pending, the coming weeks will test whether this fragile technical recovery can withstand the weight of the courtroom.
Ad
Bayer Stock: New Analysis - 5 June
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
